BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 10931834)

  • 1. NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer.
    Kanda K; Hu HM; Zhang L; Grandchamps J; Boxer LM
    J Biol Chem; 2000 Oct; 275(41):32338-46. PubMed ID: 10931834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of c-myc promoter P1 by immunoglobulin kappa gene enhancers in Burkitt lymphoma: functional characterization of the intron enhancer motifs kappaB, E box 1 and E box 2, and of the 3' enhancer motif PU.
    Wittekindt NE; Hörtnagel K; Geltinger C; Polack A
    Nucleic Acids Res; 2000 Feb; 28(3):800-8. PubMed ID: 10637333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-kappa B sites function as positive regulators of expression of the translocated c-myc allele in Burkitt's lymphoma.
    Ji L; Arcinas M; Boxer LM
    Mol Cell Biol; 1994 Dec; 14(12):7967-74. PubMed ID: 7969136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
    Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
    Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells.
    Madisen L; Groudine M
    Genes Dev; 1994 Sep; 8(18):2212-26. PubMed ID: 7958890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the c-myc p1 promoter in Burkitt's lymphoma by the hs3 immunoglobulin heavy-chain gene enhancer.
    Hu HM; Kanda K; Zhang L; Boxer LM
    Leukemia; 2007 Apr; 21(4):747-53. PubMed ID: 17287852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Myc-associated zinc finger protein-related factor binding site is required for the deregulation of c-myc expression by the immunoglobulin heavy chain gene enhancers in Burkitt's lymphoma.
    Hu HM; Arcinas M; Boxer LM
    J Biol Chem; 2002 Mar; 277(12):9819-24. PubMed ID: 11777933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.
    Duan H; Heckman CA; Boxer LM
    Oncogene; 2007 Apr; 26(18):2635-41. PubMed ID: 17043638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of immunoglobulin kappa elements in c-myc activation.
    Hörtnagel K; Mautner J; Strobl LJ; Wolf DA; Christoph B; Geltinger C; Polack A
    Oncogene; 1995 Apr; 10(7):1393-401. PubMed ID: 7731690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory elements in the immunoglobulin kappa locus induce c-myc activation and the promoter shift in Burkitt's lymphoma cells.
    Polack A; Feederle R; Klobeck G; Hörtnagel K
    EMBO J; 1993 Oct; 12(10):3913-20. PubMed ID: 8404859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
    Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
    Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
    Jain VK; Judde JG; Max EE; Magrath IT
    J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
    Wang J; Boxer LM
    J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunoglobulin heavy chain locus control region increases histone acetylation along linked c-myc genes.
    Madisen L; Krumm A; Hebbes TR; Groudine M
    Mol Cell Biol; 1998 Nov; 18(11):6281-92. PubMed ID: 9774645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant downregulation of IgH 3' enhancer activity and c-myc expression in a plasmacytoma x fibroblast environment: implications for dysregulation of translocated c-myc.
    Thøger Andersen AS; Jensen AW; Grant P; Arulampalam V; Pettersson S; Junker S
    Mol Immunol; 1997 Feb; 34(2):97-107. PubMed ID: 9188842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
    Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
    Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TATA box and Sp1 sites mediate the activation of c-myc promoter P1 by immunoglobulin kappa enhancers.
    Geltinger C; Hörtnagel K; Polack A
    Gene Expr; 1996; 6(2):113-27. PubMed ID: 8979089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NF-kappa B and Oct-2 synergize to activate the human 3' Igh hs4 enhancer in B cells.
    Sepulveda MA; Emelyanov AV; Birshtein BK
    J Immunol; 2004 Jan; 172(2):1054-64. PubMed ID: 14707079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2.
    Heckman CA; Cao T; Somsouk L; Duan H; Mehew JW; Zhang CY; Boxer LM
    Cancer Res; 2003 Oct; 63(20):6666-73. PubMed ID: 14583460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the promoter for human immunoglobulin gamma3 germ-line transcription and its interaction with the 3'alpha enhancer.
    Pan Q; Petit-Frére C; Stavnezer J; Hammarström L
    Eur J Immunol; 2000 Apr; 30(4):1019-29. PubMed ID: 10760789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.